{{Promotional|date=March 2026}} {{Short description|American lawyer}} {{Infobox person | honorific_prefix = | name = Kevin Outterson | honorific_suffix = | birth_date = <!-- {{Birth date and age|YYYY|MM|DD}} for living people supply only the year with {{Birth year and age|YYYY}} unless the exact date is already widely published, as per WP:DOB. For people who have died, use {{Birth date|YYYY|MM|DD}}. --> | birth_place = | baptised = <!-- will not display if birth_date is entered --> | disappeared_date = <!-- {{Disappeared date and age|YYYY|MM|DD|YYYY|MM|DD}} (disappeared date then birth date) --> | disappeared_place = | disappeared_status = | death_date = <!-- {{Death date and age|YYYY|MM|DD|YYYY|MM|DD}} (enter DEATH date then BIRTH date (e.g., ...|1908|31|8|1967|28|2}} use both this parameter and |birth_date to display the person's date of birth, date of death, and age at death) --> | death_place = | death_cause = | body_discovered = | resting_place = | resting_place_coordinates = <!-- {{coord|LAT|LONG|type:landmark|display=inline}} --> | burial_place = <!-- may be used instead of resting_place and resting_place_coordinates (displays "Burial place" as label) --> | burial_coordinates = <!-- {{coord|LAT|LONG|type:landmark|display=inline}} --> | monuments = | alma_mater = Northwestern University University of Cambridge University of Reading | occupation = Law professor | years_active = | era = | employer = Boston University School of Law | organization = | agent = <!-- Discouraged in most cases, specifically when promotional, and requiring a reliable source --> | known_for = Health Law, Intellectual Property Law, Antibiotic Resistance | notable_works = <!-- produces label "Notable work"; may be overridden by |credits=, which produces label "Notable credit(s)"; or by |works=, which produces label "Works"; or by |label_name=, which produces label "Label(s)" --> | style = | height = <!-- "X cm", "X m" or "X ft Y in" plus optional reference (conversions are automatic) --> | television = | title = <!-- Formal/awarded/job title. The parameter |office=may be used as an alternative when the label is better rendered as "Office" (e.g. public office or appointments) --> | term = | predecessor = | successor = | party = | movement = | opponents = | boards = | criminal_charges = <!-- Criminality parameters should be supported with citations from reliable sources --> | criminal_penalty = | criminal_status = | spouse = <!-- Use article title or common name --> | partner = <!-- (unmarried long-term partner) --> | children = | parents = <!-- overrides mother and father parameters --> | mother = <!-- may be used (optionally with father parameter) in place of parents parameter (displays "Parent(s)" as label) --> | father = <!-- may be used (optionally with mother parameter) in place of parents parameter (displays "Parent(s)" as label) --> | relatives = | family = | callsign = | awards = | website = <!-- {{URL|example.com}} --> | module = | module2 = | module3 = | module4 = | module5 = | module6 = | signature = | signature_size = | signature_alt = | footnotes = }} '''Kevin Outterson''' is a lawyer, a professor of law and the Austin B. Fletcher Professor Boston University School of Law (2023-present).<ref>{{Cite web |title=Kevin Outterson {{!}} School of Law |url=https://www.bu.edu/law/profile/kevin-outterson/ |access-date=2022-08-24 |website=www.bu.edu |language=en}}</ref> He is also the executive director<ref>{{Cite web |title=KEVIN OUTTERSON, ESQ. |url=https://carb-x.org/team/kevin-outterson-esq/ |access-date=2022-08-24 |website=Carb-X |language=en-US}}</ref> of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator ([https://carb-x.org/ CARB-X]), a global non-profit partnership that supports companies<ref>{{Cite web |title=Overview |url=https://carb-x.org/about/overview/ |access-date=2022-08-24 |website=Carb-X |language=en-US}}</ref> developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections.
CARB-X receives funding from a global consortium of governments and foundations. These include the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR); Wellcome Trust, a global charitable foundation; the UK Government's Global Antimicrobial Resistance Innovation Fund (UK GAMRIF); the Gates Foundation; Germany's Federal Ministry of Research, Technology, and Space (BMFTR); the government of Canada; the Novo Nordisk Foundation; Italy's Ministry of Economy and Finance, and Japan's Ministry of Health. CARB-X also receives in-kind support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). In 2022, CARB-X received a new commitment of funding<ref>{{Cite web |date=May 19, 2022 |title=CARB-X |url=https://carb-x.org/carb-x-news/u-s-government-and-wellcome-commit-an-additional-us370-million-to-carb-x/}}</ref> from BARDA and Wellcome of up to $370 million. In 2023, the German and UK governments renewed funding to CARB-X, committing an additional €41 million and £24 million; the government of Canada committed CAD$6.3 million over two years; and The Novo Nordisk Foundation committed USD$25 million over three years.
The G7 Health Ministers have cited CARB-X<ref>{{Cite web |date=May 20, 2022 |title=G7 Health Ministers' Communiqué |url=https://www.g7germany.de/resource/blob/974430/2042058/5651daa321517b089cdccfaffd1e37a1/2022-05-20-g7-health-ministers-communique-data.pdf |website=G7 Germany}}</ref> among the critical initiatives to support as the G7 governments renew their 2021 commitment to address the most dangerous drug-resistant infections. In May 2023, the global threat of Antimicrobial Resistance and the importance off supporting CARB-X as a global push incentive that coordinates and accelerates much-needed antibacterial innovation was featured in G7 Hiroshima Leaders’ Communiqué<ref>[https://www.mofa.go.jp/files/100506878.pdf G7 Hiroshima Leaders’ Communiqué] (PDF). ''G7 Japan.'' May 20, 2023.</ref> and the G7 Nagasaki Health Ministers’ Communiqué.<ref>[https://www.mhlw.go.jp/content/10500000/001096403.pdf G7 Nagasaki Health Ministers’ Communiqué] (PDF). ''G7 Japan.'' May 13, 2023.</ref> The same year, G20 Health Ministers cited CARB-X as playing a critical role in accelerating antimicrobial R&D and access.<ref>[https://www.g20.in/content/dam/gtwenty/gtwenty_new/document/G20_HMM_Outcome_Document_and_Chair_Summary.pdf G20 Health Ministers' Outcome Document] {{Webarchive|url=https://web.archive.org/web/20240628133554/https://www.g20.in/content/dam/gtwenty/gtwenty_new/document/G20_HMM_Outcome_Document_and_Chair_Summary.pdf |date=2024-06-28 }} (PDF). ''G20 India''. August 19, 2023.</ref> In May 2024, the Antimicrobial Resistance (AMR) Multi-Stakeholder Partnership Platform issued a call for actionable steps to address the rising threat of AMR ahead of the United Nations General Assembly High-Level Meeting on AMR in September 2024. The call recommended increasing public investment in push incentives to catalyze global antimicrobial R&D efforts and cited CARB-X as a push mechanism that should be mobilized due to CARB-X’s critical role in supporting the discovery and development or new antimicrobials.<ref>[https://openknowledge.fao.org/server/api/core/bitstreams/f252d9e2-91f2-48d7-a20c-50da25539234/content Call for actionable steps in response to the rising threat of antimicrobial resistance (AMR)] {{Webarchive|url=https://web.archive.org/web/20240515195707/https://openknowledge.fao.org/server/api/core/bitstreams/f252d9e2-91f2-48d7-a20c-50da25539234/content |date=2024-05-15 }} ''Antimicrobial Resistance (AMR) Multi-Stakeholder Partnership Platform.'' May 2024.</ref>
Outterson's research focuses primarily on the law and economics of antibiotic resistance–including push and pull incentives–health law, intellectual property, and global access to medicine.<ref name="bio">{{cite web |title=Kevin Outterson {{!}} School of Law |url=http://www.bu.edu/law/profile/kevin-outterson/ |website=www.bu.edu |accessdate=12 May 2020}}</ref>
Outterson has testified before Congress, the World Health Organization (WHO), UK Parliamentary working groups, and for the District of Columbia, Massachusetts, Vermont, California and West Virginia state legislatures.<ref>{{Cite web |date=July 2015 |title=Boston University |url=https://www.bu.edu/law/files/2015/07/Kevin-Outterson.pdf}}</ref>
He is co-director of the health law program at Boston University School of Law (2007–present) and associate fellow at the Royal Institute of International Affairs at Chatham House,<ref>{{Cite web |title=Kevin Outterson |url=https://www.chathamhouse.org/about-us/our-people/kevin-outterson |access-date=2022-08-24 |website=Chatham House – International Affairs Think Tank |language=en}}</ref> London (2014–present). He served on the Board of the American Society of Law, Medicine & Ethics, and serves as faculty editor to th''e American Journal of Law & Medicine'' (2007–present). He is past editor-in-chief of the ''Journal of Law, Medicine & Ethics'' (2010–2016).<ref name="bio"/>
==References== {{Reflist}}
==External links== *{{Google Scholar id|m4to2LMAAAAJ}} *"[https://www.bostonglobe.com/2020/08/05/magazine/racing-clock-stop-drug-resistant-superbugs/ Racing the clock to stop drug-resistant superbugs]" The Boston Globe by Maryn McKenna *"[https://www.nature.com/articles/nrd.2016.155 Accelerating global innovation to address antibacterial resistance: introducing CARB-X]" Nature Reviews Drug Discovery *"[https://www.bu.edu/articles/2022/can-we-prevent-antibiotic-resistance/ Can we prevent antibiotic resistance?]" [https://www.bu.edu/brink/ The Brink] by [http://robinberghaus.com/ Robin Berghaus] *"[https://www.bostonglobe.com/2022/07/18/opinion/antibiotic-resistant-infections-could-dwarf-covid-19-pandemic/ Antibiotic-resistant infections could dwarf the COVID-19 pandemic]" The Boston Globe by Kevin Outterson and [https://www.linkedin.com/in/henryskinner/ Henry Skinner] *"[https://www.bloomberg.com/news/articles/2022-05-24/antibiotics-price-stalls-development-to-counter-superbugs A better way to fund the fight against superbugs]" Bloomberg by [https://www.linkedin.com/in/patonj/ James Paton] *"[https://www.bizjournals.com/boston/news/2022/05/20/antibacterial-resistance.html The battle against bugs]" Boston Business Journal by [https://www.linkedin.com/in/rowanwalrath/ Rowan Walrath] *"[https://www.progresspotentialpossibilities.com/podcast/episode/7af500c0/dr-erin-duffy-phd-and-kevin-outterson-esq-combating-antibiotic-resistant-bacteria-carb-x Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)]" Progress, Potential, and Possibilities hosted by [https://www.linkedin.com/in/iraspastor/ Ira Pastor] *"[https://www.fightinfectiousdisease.org/infectious-conversations The Global Burden of AMR]" Infectious Conversations hosted by [https://www.linkedin.com/in/candace-dematteis-01a60236/ Candace DeMatteis], [https://www.fightinfectiousdisease.org/ Partnership to Fight Infectious Disease] *"[https://podcasts.apple.com/us/podcast/antibiotic-resistance-how-carb-x-helps-new-companies/id1566190374?i=1000538483945 Antibiotic Resistance: How CARB-X Helps New Companies Get a Running Start]" The State of Health with [https://www.linkedin.com/in/gunnar-esiason-676403126/ Gunnar Esiason] {{Authority control}}
{{DEFAULTSORT:Outterson, Kevin}} Category:Year of birth missing (living people) Category:Living people Category:Boston University faculty Category:American lawyers Category:Northwestern University alumni Category:Medical journal editors